28 F. Supp. 3d 282
D.N.J.2014Background
- Plaintiff Maria Mendez underwent spinal surgery in 2011 by Dr. Shah, receiving Medtronic devices including Infuse/LT-Cage and Capstone components.
- Postoperative imaging showed cage migration, leading to a May 2011 revision with a different Capstone spacer and continued pain and disability.
- Plaintiff alleges multiple damages from the surgeries, including drop foot, ongoing pain, and disability, and asserts several product-related theories.
- Plaintiff sues Medtronic entities for negligence, medical malpractice, warranty breaches, fraud, PLA claims, and third-party beneficiary theory, seeking damages.
- Defendants move to dismiss various claims on grounds of federal preemption under the MDA and pleading deficiencies; some claims survive with amendment, others are dismissed.
- The court has diversity jurisdiction and applies New Jersey law to state-law claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Does the PLA preempt state-law warranty and tort claims | Plaintiff argues parallel state claims survive when not conflicting with FDA requirements. | Medtronic contends preemption bars state-law claims relating to FDA-approved PMA device. | Some PLA claims are preempted; others survive with amendment. |
| Is Plaintiff's implied warranty claim subsumed by the PLA | PLA does not bar implied warranty under UCC principles. | PLA precludes implied warranty claims as part of product liability framework. | Implied warranty claim dismissed as subsumed by PLA. |
| Is Plaintiff's breach of express warranty claim adequately pled | Medtronic made express warranties through marketing and conduct beyond FDA labeling. | Plaintiff fails to identify the exact language of the warranty or its source. | Dismissed without prejudice; leave to amend to plead specific language and devices. |
| Are PLA claims for design/manufacturing/warnings defects preempted or viable | Claims of design/manufacturing defects and inadequate warnings aren’t preempted if parallel to FDA requirements. | Some design defects are preempted where PMA approved packaging or system design is involved. | Design defect claim dismissed as preempted; manufacturing defect claim viable subject to parallelism; failure-to-warn claim not barred and allowed to proceed with further detail. |
| Is the Third Party Beneficiary claim viable | Medicare beneficiary is a third-party to the CIA and may sue. | CIA does not contemplate third-party enforcement by Medicare beneficiaries. | Dismissed for lack of intended third-party beneficiary rights. |
| Is the fraud/misrepresentation claim subsumed by the PLA | Misrepresentations in advertising/promotions are distinct from product defect and could support CFA/claims. | Fraud claims are subsumed by PLA when the heart of the claim is harm from a defective product. | Fraud/misrepresentation claim dismissed as subsumed under the PLA. |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (U.S. 2008) (express preemption of state-law claims for PMA devices; requires federal requirements and parallelism test)
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (U.S. 1996) (class III device PMA vs 510(k) substantial equivalence; parallel state duties)
- Buckman Co. v. Plaintiffs’ Legal Committee, 531 U.S. 341 (U.S. 2001) (fraud-on-the-FDA claims preemption; limits on state-law claims interfering with FDA processes)
- In re Medtronic Sprint Fidelis Leads Prods. Liab. Litig., 623 F.3d 1200 (8th Cir. 2010) (preemption/parallel claims for manufacturing defects and PMA devices; guidance on parallel claims)
- Perez v. Nidek Co., Ltd., 711 F.3d 1109 (9th Cir. 2013) (paralleling state duties with federal requirements and preemption considerations)
- Lewis v. American Cyanamid Co., 155 N.J. 544 (N.J. 1998) (design defect risk-utility analysis under New Jersey product liability law)